HROW HARROW, INC.
8-K Current Report
Filed: March 2, 2026
Health Care
Pharmaceutical PreparationsHARROW, INC. (HROW) 8-K current report filed with SEC EDGAR on March 2, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 2.02: Results of Operations and Financial Condition
- Item 7.01: Regulation FD Disclosure
AI Filing Analysis8-K
Item 2.02 · Results of Operations and Financial Condition
- • Q4 and full-year 2025 earnings released March 2, 2026 — financials in Exhibits 99.1 (press release) and 99.2 (stockholder letter)
- • Stockholder letter signals potential qualitative updates on corporate strategy or business developments beyond raw financials
Item 7.01 · Regulation FD Disclosure
- • Investor presentation (Exhibit 99.3) filed for use at conferences and investor meetings — signals active investor outreach
- • Reg FD disclosure ensures material info shared broadly, not selectively — standard compliance move with no new standalone financials disclosed
Other HARROW, INC. 8-K Filings
Get deeper insights on HARROW, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.